Arcturus Therapeutics (ARCT) to Release Earnings on Thursday

Arcturus Therapeutics (NASDAQ:ARCT) is scheduled to be releasing its earnings data after the market closes on Thursday, November 7th. Analysts expect Arcturus Therapeutics to post earnings of ($0.70) per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its earnings results on Monday, August 5th. The biotechnology company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($1.85) by $1.21. The business had revenue of $49.86 million for the quarter, compared to the consensus estimate of $21.00 million. Arcturus Therapeutics had a negative return on equity of 25.47% and a negative net margin of 41.21%. During the same period in the previous year, the business earned ($1.98) EPS. On average, analysts expect Arcturus Therapeutics to post $-3 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Arcturus Therapeutics Price Performance

Shares of ARCT opened at $18.35 on Wednesday. The company has a market capitalization of $494.17 million, a P/E ratio of -7.14 and a beta of 2.64. Arcturus Therapeutics has a one year low of $17.26 and a one year high of $45.00. The business’s 50 day simple moving average is $20.74 and its 200-day simple moving average is $24.39.

Insiders Place Their Bets

In other Arcturus Therapeutics news, COO Pad Chivukula sold 12,000 shares of the company’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $20.76, for a total transaction of $249,120.00. Following the completion of the sale, the chief operating officer now owns 435,334 shares in the company, valued at approximately $9,037,533.84. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 15.30% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on ARCT. Cantor Fitzgerald reissued an “overweight” rating on shares of Arcturus Therapeutics in a report on Monday, September 9th. Leerink Partnrs raised Arcturus Therapeutics to a “strong-buy” rating in a report on Monday, August 12th. HC Wainwright reaffirmed a “buy” rating and set a $63.00 price objective on shares of Arcturus Therapeutics in a report on Tuesday, October 1st. Finally, Leerink Partners initiated coverage on Arcturus Therapeutics in a report on Monday, August 12th. They set an “outperform” rating and a $70.00 price objective on the stock. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $71.40.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.